Abstract
Background
Ampullary carcinoma is a rare malignancy. Despite radical resection, survival rates remain low with high rates of local failure. We performed a single-institution outcomes analysis to define the role of concurrent chemoradiotherapy (CRT) in addition to surgery.
Methods
A retrospective analysis was performed of all patients undergoing potentially curative pancreaticoduodenectomy for adenocarcinoma of the ampulla of Vater at Duke University Hospitals between 1976 and 2009. Time-to-event analysis was performed comparing all patients who underwent surgery alone to the cohort of patients receiving CRT in addition to surgery. Local control (LC), disease-free survival (DFS), overall survival (OS), and metastases-free survival (MFS) were estimated using the Kaplan–Meier method.
Results
A total of 137 patients with ampullary carcinoma underwent Whipple procedure. Of these, 61 patients undergoing resection received adjuvant (n = 43) or neoadjuvant (n = 18) CRT. Patients receiving chemoradiotherapy were more likely to have poorly differentiated tumors (P = .03). Of 18 patients receiving neoadjuvant therapy, 67% were downstaged on final pathology with 28% achieving pathologic complete response (pCR). With a median follow-up of 8.8 years, 3-year local control was improved in patients receiving CRT (88% vs 55%, P = .001) with trend toward 3-year DFS (66% vs 48%, P = .09) and OS (62% vs 46%, P = .074) benefit in patients receiving CRT.
Conclusions
Long-term survival rates are low and local failure rates high following radical resection alone. Given patterns of relapse with surgery alone and local control benefit in patients receiving CRT, the use of chemoradiotherapy in selected patients should be considered.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chareton B, Coiffic J, Landen S, Bardaxoglou E, Campion JP, Launois B. Diagnosis and therapy for ampullary tumors: 63 cases. World J Surg. 1996;20:707–12.
Mehta V, Fisher GA, Ford JM, Poen JC, Vierra MA, Oberhelman HA, et al. Adjuvant chemoradiotherapy for “unfavorable” carcinoma of the ampulla of Vater: preliminary report. Arch Surg. 2001;136:65–9.
Sikora SS, Balachandran P, Dimri K, Rastogi N, Kumar A, Saxena R, et al. Adjuvant chemo-radiotherapy in ampullary cancers. Eur J Surg Oncol. 2005;31:158–63.
Sarmiento JM, Nagomey DM, Sarr MG, Farnell MB. Periampullary cancers: Are there differences? Surg Clin North Am. 2001;81:543–55.
Allema JH, Reinders ME, van Gulik TM, van Leeuwen DJ, Verbeek PC, de Wit LT, et al. Results of pancreaticoduodenectomy for ampullary carcinoma and analysis of prognostic factors for survival. Surgery. 1995;117:247–53.
Willett CG, Warshaw AL, Convery K, Compton CC. Patterns of failure after pancreaticoduodenectomy for ampullary carcinoma. Surg Gynecol Obstet. 1993;176:33–8.
Duffy JP, Hines OJ, Liu JH, Ko CY, Cortina G, Isacoff WH, et al. Improved survival for adenocarcinoma of the ampulla of Vater: Fifty-five consecutive resections. Arch Surg. 2003;138:941–8; discussion 948–950.
Lee JH, Whittington R, Williams NN, Berry MF, Vaughn DJ, Haller DG, et al. Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas. Int J Radiat Oncol Biol Phys. 2000;47:945–53.
Barton RM, Copeland EM, 3rd. Carcinoma of the ampulla of Vater. Surg Gynecol Obstet. 1983;156:297–301.
Kopelson G, Galdabini J, Warshaw AL, Gunderson LL. Patterns of failure after curative surgery for extra-hepatic biliary tract carcinoma: Implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 1981;7:413–7.
Monson JR, Donohue JH, McEntee GP, McIlrath DC, van Heerden JA, Shorter RG, et al. Radical resection for carcinoma of the ampulla of Vater. Arch Surg. 1991;126:353–7.
Todoroki T, Koike N, Morishita Y, Kawamoto T, Ohkohchi N, Shoda J, et al. Patterns and predictors of failure after curative resections of carcinoma of the ampulla of Vater. Ann Surg Oncol. 2003;10:1176–83.
Krishnan S, Rana V, Evans DB, Varadhachary G, Das P, Bhatia S, et al. Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of Vater. Int J Radiat Oncol Biol Phys. 2008;70:735–43.
Bhatia S, Miller RC, Haddock MG, Donohue JH, Krishnan S. Adjuvant therapy for ampullary carcinomas: The Mayo clinic experience. Int J Radiat Oncol Biol Phys. 2006;66:514–9.
Kim K, Chie EK, Jang JY, Kim SW, Oh DY, Im SA, et al. Role of adjuvant chemoradiotherapy for ampulla of vater cancer. Int J Radiat Oncol Biol Phys. 2009;75:436–41.
Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Ann Surg. 1999;230:776–84.
Alden ME, Waterman FM, Topham AK, Barbot DJ, Shapiro MJ, Mohiuddin M. Cholangiocarcinoma: Clinical significance of tumor location along the extrahepatic bile duct. Radiology. 1995;197:511–6.
Zhou J, Hsu CC, Winter JM, Pawlik TM, Laheru D, Hughes MA, et al. Adjuvant chemoradiation versus surgery alone for adenocarcinoma of the ampulla of Vater. Radiother Oncol. 2009;92:244–8.
Acknowledgment
Acknowledgment is given to Jonathan Jenkins for editorial assistance.
Funding
None.
Conflict of interest
None related to the subject matter of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
Presentations: Poster Presentation at 2011 Gastrointestinal Cancers Symposium.
Rights and permissions
About this article
Cite this article
Palta, M., Patel, P., Broadwater, G. et al. Carcinoma of the Ampulla of Vater: Patterns of Failure Following Resection and Benefit of Chemoradiotherapy. Ann Surg Oncol 19, 1535–1540 (2012). https://doi.org/10.1245/s10434-011-2117-1
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-011-2117-1